Since in vitro studies [36,37,38] showed the anti-proliferative effects of VK on several cancer cells including HCC and reduced the DCP production, it was expected that VK2 might show anti-tumor effects in HCC patients. The gene discussed is ACE; the disease is hepatocellular carcinoma.